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INTRODUCTION 
Local anesthetics are classifi ed by 
their chemical structures, with the two 
major categories being esters and amides 
(Table 1). The agent of choice depends 
on the method of administration, the 
length of time for which the affected areas 
require local anesthesia, and potential 
adverse effects. 
Esters include benzocaine (Cepacol, 
Reckitt Benckiser; Dermoplast, Prestige 
Brands Holdings; Chloraseptic, Prestige 
Brands Holdings; HurriCaine, Beutlich 
Pharmaceuticals; Lanacane, Reckitt 
Benckiser; Orabase, Colgate-Palmolive 
Company; Orajel, Church & Dwight; and 
Zilactin, Blairex Laboratories); chloropro-
caine (Nesacaine, APP Pharmaceuticals); 
procaine (Novocaine, Colgate-Palmolive 
Company); and tetracaine.1
Amides include bupivacaine (Mar-
caine, Hospira; Sensorcaine, AstraZen-
eca); dibucaine (Nupercainal, Nucere 
Pharma); levobupivacaine (Chirocaine, 
Purdue Pharma); lidocaine (Dilocaine, 
Shire; Solarcaine, Bayer; Lidoderm, 
Endo Pharmaceuticals;  and Xylocaine, 
Fresenius Kabi USA); mepivacaine (Car-
bocaine, Cooke-Waite; Isocaine, Novo-
col Pharmaceutical; Polocaine, Novocol 
Pharmaceutical); prilocaine (Citanest, 
Dentsply Pharmaceutical); and ropiva-
caine (Naropin, Fresenius Kabi).1
Some combination products contain 
both amides and esters; the most com-
monly used of these agents include lido-
caine/prilocaine (Emla, Akorn, Inc.) and 
benzocaine/tetracaine/butamben (Ceta-
caine, Cetylite Industries).1 
Amides have largely replaced the 
esters because they produce fewer 
adverse effects and generally have a lon-
ger duration of action.1
Pramoxine (Analpram, Sebela Pharma-
ceuticals; Itch-X, B. F. Ascher & Company; 
Pramegel, Pharmaderm; Pramosone, 
Sebela Pharmaceuticals; Prax, Ferndale 
Laboratories;  and Tronolane, Abbott 
Laboratories) is a local anesthetic that 
does not belong to either the amide or 
ester class.1
Local anesthesia can be achieved by 
various methods, including topical admin-
istration, infi ltration, fi eld block, nerve 
block, and intravenous regional injection. 
The method by which a local anesthetic 
is administered aids its effectiveness 
by delivering the agent directly to the 
area that is causing or will cause pain. 
This decreases systemic absorption and 
related toxic effects. Systemic absorption 
could produce toxic effects on both the 
cardiovascular and nervous systems.1
Recently, topical anesthetics have been 
reported to cause methemoglobinemia, 
an elevated fraction of methemoglobin (an 
unstable type of hemoglobin within eryth-
rocytes). The popularity of benzocaine as 
Disclosure: The authors report no commer-
cial or fi nancial relationships in regard to this 
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Welcome to the Pharmacovigilance Forum, 
where we report on interesting adverse drug 
reactions (ADRs), including drug-induced disease. 
ADRs are a leading cause of morbidity and mortal-
ity. The Institute of Medicine has estimated that 
44,000 to 98,000 deaths 
occur annually from medi-
cal errors, with 7,000 due 
to ADRs. Studies suggest 
that 6.7% of hospitalized 
patients have a serious 
ADR; about 0.5% die as a 
consequence. ADRs are a 
signiﬁ cant, preventable public health problem 
that we can help mitigate through education. 
Drug approvals in the U.S. continue to grow. 
In 2015, the Food and Drug Administration (FDA) 
approved 45 novel drugs—up from an average 
of about 28 per year from 2006 through 2014. 
This is a signiﬁ cant increase, especially since 
many of these approvals involved complex bio-
logic agents. Yet all pharmaceuticals carry a risk 
of ADRs, whether they are new and improved, 
generic agents, older brand products, complex 
biologics, or biosimilars. Publishing ADR cases is 
a great way to educate others about little-known 
reactions, unique patient management of a 
reaction, or interesting presentations of known 
reactions to a drug or drug class. 
Each Pharmacovigilance Forum will discuss 
noteworthy topics related to ADRs in the clini-
cal realm. Every medication has the potential to 
cause disease, but clinicians are often slow to 
recognize drug therapy as an etiological factor. 
I encourage anyone with a potentially interest-
ing case to contact me, to publish ADRs here 
or elsewhere, and to report ADRs to the FDA 
MedWatch program.
—Michele B. Kaufman
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a topical anesthetic has diminished as a 
result of increasing concerns regarding 
its potential to induce this hematological 
disorder. Numerous case reports have 
been published.2–17 As of 2009, a review 
of 242 published cases implicated ben-
zocaine in 66% of methemoglobinemia 
related to local anesthesia, while lidocaine 
accounted for only about 5% of cases.13
PATHOPHYSIOLOGY
Hemoglobin is composed of four 
heme groups: deoxyhemoglobin, oxy-
hemoglobin, carboxyhemoglobin, and 
methemoglobin. Each group contains 
an iron atom capable of binding oxygen. 
This binding, however, can occur only 
if the iron is in the reduced state (Fe+2). 
The removal of an electron from reduced 
iron—oxidizing it from Fe+2 to Fe+3—pro-
duces methemoglobin. In addition, the 
production of a ferric (Fe+3) heme group 
interferes with oxygen unloading by the 
other ferrous (Fe+2) heme groups on the 
hemoglobin molecule. Red blood cells are 
continuously under stress by oxidative 
processes and undergo numerous struc-
tural changes that result in the formation 
of methemoglobin. The development of 
methemoglobin is regulated by various 
enzymatic processes, which include the 
major pathway nicotinamide adenine 
dinucleotide methemoglobin reductase 
and the minor pathway nicotinamide ade-
nine dinucleotide phosphate (NADPH) 
methemoglobin reductase.2,4,7,9 A small 
amount of methemoglobin is reduced via 
nonenzymatic pathways, such as by ascor-
bic acid, reduced glutathione, riboflavin, 
and cysteine.5 During these major and 
minor processes, iron is in the ferrous 
form (Fe+2) and combines with oxygen for 
transportation to the tissues.2,4,7–9
Because methemoglobin prevents oxy-
gen transport to cells, patients present-
ing with methemoglobinemia become 
cyanotic despite an adequate respira-
tory status. Increased oxygenation has 
no effect on either the cyanotic state or 
oxygen saturation. Pulse oximetry will 
most likely be inaccurate, and readings 
will be inconsistent with the patient’s 
increasing cyanosis.5 Oxygen saturation 
measured by pulse oximetry is typically 
in the range of 80% to 85% regardless of 
the severity of methemoglobinemia.4 Rou-
tine analysis of arterial blood gas is used 
to determine the partial pressure of oxy-
gen (PO2), which is then used to calculate 
oxygen saturation in the blood. However, 
the measurement of PO2 is not affected by 
the presence of methemoglobin, and as a 
result, pulse oximetry readings that are 
inconsistent with oxygen saturation are 
suggestive of methemoglobin.4,5 
A pulse oximeter is a noninvasive 
device attached to the finger, earlobe, 
or nose that emits two separate wave-
lengths of light, red (660 nm) and infrared 
(940 nm). A co-oximeter is used to meas-
ure the absorbance of oxyhemoglobin  and 
deoxyhemoglobin circulating throughout 
the capillaries. It reflects the amount of 
oxygen in the blood, expressed as a per-
centage, measuring light absorbance at 
four different wavelengths, correlating to 
the absorption characteristics off all four 
heme groups.18 Carboxy hemoglobin has 
an almost identical absorption spectrum 
(660 nm) to that of oxyhemoglobin.18 
Methemoglobin absorbs light at both 
wavelengths (660 nm and 940 nm) that 
standard oximeters emit.18 Therefore, a 
definitive diagnosis should be confirmed 
by co-oximetry in patients who present 
with cyanosis of an uncertain cause. 
A “filter paper test” provides a rapid 
bedside method for diagnosing methe-
moglobin. In patients with this disorder, 
arterial blood, when drawn and placed on 
the filter paper, is often chocolate brown 
or black and does not change color when 
exposed to oxygen.4,5,9
The clinical manifestations of methemo-
globinemia directly correlate with the level 
of measured methemoglobin. Symptoms 
can be worse in those at age extremes 
(e.g., very young or very old) or with mul-
tiple comorbidities. Elderly and pediatric 
patients, as well as hypoxic patients, are 
more prone to the formation of methemo-
globin. Neonates express low levels of func-
tional NADPH methemoglobin reductase, 
and this enzyme becomes less efficient 
in the elderly.17 A normal methemoglobin 
level is less than 1% to 3% of the fraction 
of hemoglobin in healthy individuals. 
When the methemoglobin level indicated 
through arterial co-oximetry is 15% to 20%, 
patients are usually cyanotic, but they may 
be asymptomatic. When methemoglobin 
levels reach 20% to 50%, the patient may 
experience headache and lightheadedness, 
weakness, chest discomfort, palpitations, 
and dyspnea. Death can occur when met-
hemoglobin levels exceed 70%.2,5–7,10
Methemoglobinemia usually results 
from exposure to an external oxidizing 
agent that compromises the physiologi-
cal cellular defenses of red blood cells. 
The disorder can also be hereditary. It is 
associated with the production of abnor-
mal hemoglobin, which usually presents 
as cyanosis at birth or as a secondary 
feature of NADH reductase deficiency.5,12 
Exogenous agents that pose a risk for 
methemoglobinemia are listed in Table 2.
PRINCIPLES OF TREATMENT 
AND REPLACEMENT
The topical anesthetics benzocaine 
20% (HurriCaine spray) and lidocaine 
are readily available in most emergency 
departments and are commonly used 
to anesthetize a patient’s airway before 
elective endotracheal intubations or endo-
scopic procedures.14 Both agents have 
been reported to cause methemoglobin-
emia. A recent review of the literature 
indicated that methemoglobinemia was 
reported more frequently with spray ben-
zocaine used during dental or  endoscopic 
procedures (such as for transesophageal 
echocardiography).14 The potentially fatal 
effects of benzocaine may be due to a 
toxic metabolite, an N-hydroxy derivative 
that has an aniline group incorporated 
into its structure.6,14 This compound has 
oxidizing properties. 
Table 2  Selected Agents Associated 
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From November 1997 through March 
2002, 132 cases of methemoglobinemia 
associated with benzocaine administra-
tion were reported to the FDA. In 123 
of these cases (93%), the product was 
a spray; in two cases, the product was 
a benzocaine-containing lozenge; and 
in one case, it was a gel.14 These per-
centages may not accurately represent 
actual occurrence rates because cases 
were likely underreported. For example, 
patients with mild methemoglobinemia 
may be asymptomatic or may present 
with only mild symptoms, which may 
not be recognized as potential cases 
of drug-induced methemoglobinemia. 
Differences in absorption and metabo-
lism may explain the variability of ben-
zocaine-induced methemoglobinemia in 
these individuals.6,14
Mild methemoglobinemia can be 
treated with supplemental oxygen to 
maximize the oxygen-carrying capacity 
of the remaining normal hemoglobin after 
removal of the causative agent. These 
cases generally do not require specifi c 
treatment.4,5 Symptomatic patients with 
methemoglobinemia presenting with 
methemoglobin levels exceeding 20% to 
30% should receive methylene blue, which 
acts as a cofactor for the enzyme NADPH 
methemoglobin reductase. Electrons are 
transferred from NADPH to methylene 
blue, which leads to a reduction of the 
heme iron to deoxyhemoglobin.9 Methy-
lene blue should be administered at an 
initial intravenous dose of 1 mg/kg to 
2 mg/kg over fi ve minutes.4,5,9 If there is 
no response, a repeat 1-mg/kg dose may 
be administered after 30 to 60 minutes.5,9
The adverse effects of methylene blue 
include bluish skin discoloration (which 
can complicate the assessment of cyano-
sis), hemolysis, gastrointestinal distress, 
bladder irritation, and rebound methe-
moglobinemia, particularly with doses 
that exceed 7 mg/kg.4,5,9 Methylene blue 
should not be administered to patients 
with glucose-6-phosphate dehydrogenase 
(G6PD) defi ciency or with congenital 
abnormal hemoglobin or NADH reduc-
tase defi ciency. Low levels of NADPH are 
present in these patients, and as a result, 
methylene blue will be ineffective and will 
ultimately cause hemolysis. Exchange 
transfusions should be considered in 
these individuals.4,5,7,9
Case Report
The following report describes a patient 
with benzocaine-induced methemoglobin-
emia who was seen at our hospital.
A 46-year-old woman with a medical his-
tory of hypertension, anemia, depression, 
and morbid obesity (which persisted after a 
gastric bypass in 2003) presented on April 3, 
2013, for laparoscopic fi stula repair and revi-
sion of her 2003 gastric bypass. She felt 
well at discharge, but soon afterward she 
experienced chest pain that “felt as though 
an elephant was sitting on her chest.” She 
presented to the emergency department 
on April 12. An upper gastrointestinal series 
and computed tomogra-
phy revealed free air in 
the upper abdomen and a 
large extraluminal contrast 
collection posterior to the 
gastric pouch, with free 
air bubbles in the upper 
quadrant. She decompen-
sated, and a nasogastric 
(NG) tube was temporarily 
placed. After removal of 
the NG tube, benzocaine 
20% topical oral spray 
(HurriCaine) was ordered, 
with nursing instructions 
to apply one spray to the 
back of the throat. The 
order also included instruc-
tions to repeat the spray 
every six  hours for pain 
relief. The following day, 
the nurse accidentally left 
the HurriCaine spray canis-
ter at the patient’s bedside, 
and the patient subsequently overdosed as 
the result of continuous excessive admin-
istration of the anesthetic over the next 
four days. 
On the morning of April 17, the patient 
was found to be cyanotic and “blue.” The 
patient stated that she felt short of breath, 
dizzy, and fatigued. She was immediately 
placed on 2 L of oxygen via nasal cannula. 
Later that morning, she desaturated to 83% 
and was placed on 100% fraction of inspired 
oxygen (Fi02). An arterial blood gas (ABG) 
was ordered “stat.” The ABG showed a 
methemoglobin level of 38.8%. 
At this point, the medical team con-
tacted the hematology service regarding 
therapeutic management for this patient. 
The hematology service recommended 
immediate treatment with methylene blue 
1 mg/kg, with a repeat dose one hour later 
if the methemoglobin level remained above 
20%. The patient ultimately received two 
doses of 70 mg in two hours before there 
was an initial decline in the methemoglo-
bin level (Figure 1). The patient became less 
cyanotic, and her oxygenation improved 
(Table 3). Hematology further recommended 
that the medical team continue trending the 
patient’s methemoglobin levels over the next 
24 hours. This was advised because of the 
potential for a rebound e ect, which could 
occur secondary to the presence of the circu-
lating oxidant. Repeat methylene blue doses 
were not recommended unless the patient’s 
methemoglobin level exceeded 20%. 
DISCUSSION
Numerous case reports have described 
methemoglobinemia after gastrointesti-
nal endoscopy, endotracheal intubation, 
bronchoscopic NG tube placement, and 
other inpatient procedures that involve 
prescription topical anesthetics. How-
ever, many over-the-counter (OTC) topi-
cal anesthetic gels, throat lozenges, or 
sprays can cause methemoglobinemia. 
The easy access to OTC benzocaine prod-
ucts, such as Cepacol anesthetic troches 
(Reckitt Benckiser) and Sucrets maxi-
mum-strength lozenges (Prestige Brands 
Holdings), may lead clinicians to believe 
that these products are free from adverse 
effects, including methemoglobinemia. 
Methemoglobinemia often occurs 
when the doses of benzocaine spray (or 
other local anesthetic agents) exceed 
Figure 1  Level of Methemoglobin Before 
and After Methylene Blue Treatment
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the manufacturers’ recommendations. 
Clinicians have long pointed out that 
ambiguous package instructions for 
use of the spray canisters of benzocaine 
products can be easily misinterpreted 
and can lead to potential overdoses. Pack-
age instructions commonly suggest that 
the user should “activate the spray with 
the forefinger for approximately one sec-
ond. Maximum anesthesia is produced in 
one minute.” 19 This direction could easily 
be misinterpreted to mean that a continu-
ous spray of up to one minute is permitted 
and even desirable for maximum anesthe-
sia.19 OTC benzocaine formulations may 
contain up to 20% benzocaine, and sprays 
containing benzocaine deliver 45 mg to 
60 mg of the anesthetic in one second. 
Adverse events related to topical anes-
thetics usually involve the use of multiple 
sprays or of sprays lasting longer than the 
recommended duration.3,11,20 Table 4 lists 
several strategies to reduce the risk of 
methemoglobinemia when using topical 
anesthetics.21
After discussing the potential for met-
hemoglobinemia in patients treated with 
topical anesthetics, our pharmacy depart-
ment decided to remove the HurriCaine 
spray canister from the formulary and 
replace it with unit-dose nonspray benzo-
caine (HurriCaine One), thus making it 
easier to control the amount of drug being 
administered. We continue to see benzo-
caine spray ordered for “sore throat.” Our 
staff has been educated on contacting the 
prescriber to recommend an alternative 
agent, such as benzocaine troches or loz-
enges, or phenol 0.5% spray (Chloraseptic, 
Prestige Brands Holdings), which can be 
administered to both adults and pediatric 
patients over the age of 2 years. 
CONCLUSION 
Methemoglobinemia is a persistent 
and significant clinical condition that can 
result from the use of topical anesthetics, 
among other causes. Although it is treat-
able, its detection has been complicated by 
a general lack of awareness in the medical 
community and by the limited availability 
of standard co-oximetry for an accurate 
diagnosis in the inpatient setting. Clini-
cians should be on the alert for this poten-
tially serious disorder if patients show an 
inconsistency between the oxygen satura-
tion of arterial blood and the saturation 
calculated from partial pressure of oxy-
gen. In addition, methylene blue should be 
readily available in facilities where topical 
anesthetics are administered. 
REPORTING ADVERSE  
DRUG REACTIONS
All ADRs should be reported to Med-
Watch at 1-888-INFO-FDA, 1-888-463-
6332, or online. The FDA 3500 Volun-
tary Adverse Event Report Form can be 
accessed easily online for reporting ADRs 
at www.fda.gov/Safety/Medwatch/How-
ToReport/ucm085568.htm.
The FDA is interested in serious reports 
that include any of the following patient 
outcomes: death; life-threatening condi-
tion; initial hospitalization; prolonged hos-
pitalization; disability or permanent dam-
age; congenital anomalies or birth defects; 
and other serious conditions for which 
medical or surgical intervention is needed 
to prevent one of the aforementioned out-
comes. The FDA is also interested in any 
unlabeled ADRs for new drugs.
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